A detailed history of Ars Wealth Advisors Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ars Wealth Advisors Group, LLC holds 5,564 shares of BMY stock, worth $220,668. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,564
Previous 8,199 32.14%
Holding current value
$220,668
Previous $420,000 28.33%
% of portfolio
0.04%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$47.98 - $54.4 $126,427 - $143,344
-2,635 Reduced 32.14%
5,564 $301,000
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $5.01 Million - $5.98 Million
-103,371 Reduced 92.65%
8,199 $420,000
Q3 2023

Oct 26, 2023

SELL
$57.89 - $64.73 $82,261 - $91,981
-1,421 Reduced 1.26%
111,570 $6.48 Million
Q2 2023

Jul 18, 2023

SELL
$63.71 - $70.74 $1,656 - $1,839
-26 Reduced 0.02%
112,991 $7.23 Million
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $96,987 - $110,006
-1,476 Reduced 1.29%
113,017 $7.83 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $225,778 - $267,353
-3,297 Reduced 2.8%
114,493 $8.24 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $15,312 - $9.05 Million
117,790 New
117,790 $8.37 Million
Q3 2022

Nov 08, 2022

SELL
$0.13 - $76.84 $14,705 - $8.69 Million
-113,122 Closed
0 $8.37 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $7.9 Million - $8.7 Million
108,756 Added 2490.98%
113,122 $8.71 Million
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $2,397 - $2,875
-39 Reduced 0.89%
4,366 $319,000
Q4 2021

Feb 08, 2022

SELL
$53.63 - $62.52 $53,576 - $62,457
-999 Reduced 18.49%
4,405 $275,000
Q3 2021

Oct 26, 2021

BUY
$59.17 - $69.31 $319,754 - $374,551
5,404 New
5,404 $320,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ars Wealth Advisors Group, LLC Portfolio

Follow Ars Wealth Advisors Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ars Wealth Advisors Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ars Wealth Advisors Group, LLC with notifications on news.